OBJECTIVES: To analyze the costs associated with first-line use of glatiramer acetate (GA) compared to interferon-B (INF-β) in patients with relapsing-remitting multiple sclerosis (RRMS) and spasticity from the perspective of the National Health System of Spain.   METHODS: A cost analysis of treatment and spasticity management with INF-β compared to GA for 6 months were analyzed. The clinical data were taken from the ESCALA study, which showed an improvement in spasticity in terms of spasm frequencies, muscle tone, and pain 3 and 6 months after the start of GA therapy. Unit costs for the resources used were taken from the BOTPLUS 2.0 database and available literature. The cost analysis is expressed in euros as of 2014, and a price discount of 7.5% was applied as set forth in Spanish Royal Decree 8/2010. RESULTS: The costs associated with the management of RRMS, spasticity, and relapses using GA and INF-β were €4,671.31 and €7,078.02, respectively, generating a cost savings of €2,406.72/patient, in favour of GA. CONCLUSIONS: The use of AG in the first-line treatment of patients with RRMS not only improves spasticity but it could be a strategy that offers savings cost after 6 months from the start of treatment. To initiate the treatment with AG and keep it in patients with optimal response would be a more efficient treatment option than INF-β.